Akero Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AKRO and other ETFs, options, and stocks.

About AKRO

Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. 

CEO
Andrew Cheng
CEOAndrew Cheng
Employees
56
Employees56
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
2017
Founded2017
Employees
56
Employees56

AKRO Key Statistics

Market cap
1.74B
Market cap1.74B
Price-Earnings ratio
-8.57
Price-Earnings ratio-8.57
Dividend yield
Dividend yield
Average volume
1.77M
Average volume1.77M
High today
$25.43
High today$25.43
Low today
$23.74
Low today$23.74
Open price
$24.62
Open price$24.62
Volume
834.10K
Volume834.10K
52 Week high
$58.38
52 Week high$58.38
52 Week low
$11.25
52 Week low$11.25

Analyst ratings

100%

of 9 ratings
Buy
100%
Hold
0%
Sell
0%
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.